相关实验视频
Updated: Jul 4, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.8K
在晚期黑色素瘤中,免疫检查点抑制的分离反应的瘤特征
J M Versluis1, E P Hoefsmit2, H Shehwana2
1Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cancer immunology, immunotherapy : CII
|January 27, 2024
概括
晚期黑色素瘤中对免疫检查点抑制 (ICI) 脱离反应的患者在进展性病变中显示CD8+ T细胞透和干扰素- (IFNγ) 水平增加,这表明免疫排除之外的抵抗机制.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 免疫检查点抑制 (ICI) 在晚期黑色素瘤中提供了持久的反应.
- 对ICI的分离反应是一个挑战,需要识别抵抗机制.
研究的目的:
- 调查瘤微环境中的回归性和渐进性病变之间的患者内差异,在黑色素瘤患者与 ICI 分离反应.
- 确定晚期黑色素瘤中ICI耐药性的潜在机制.
主要方法:
- 对IV期黑色素瘤患者进行回顾性分析,这些患者接受ICI治疗,表现出分离反应.
- 包括患有双重回归/渐进性病变和获得耐药样本的患者.
- 分析CD8+T细胞数量,干扰素- (IFNγ) 信号,PD-L1表达,瘤突变负担和基因突变 (B2M,PTEN,POLE).
主要成果:
- 与回归性病变相比,渐进性病变通常显示出较高的CD8+T细胞计数和IFNγ签名水平.
- 在3个病例中的2个中,在进展性病变中,瘤突变负担更高.
- 在回归性和渐进性病变之间观察到类似的PD-L1表达.
- 在一些获得性耐药性病变中发现了特定的基因突变 (B2M,PTEN,POLE).
结论:
- 患者内比较表明,分离反应中的渐进性病变并没有特征缺乏T细胞透或免疫排除.
- 研究结果表明,其他机制有助于在晚期黑色素瘤中产生ICI耐药性.
相关概念视频
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K

